---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-046197"
form_type: "8-K"
ticker: "COCH"
cik: "0001840877"
company_name: "Envoy Medical, Inc."
filed_at: "2026-04-21T23:59:59+00:00"
generated_at: "2026-05-15T05:09:30.256616+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Envoy Medical appoints Charles McKhann as Class I director and to Compensation Committee

## Summary
- Board size increased from 6 to 7 members; McKhann appointed to Compensation Committee.
- Awarded stock options for 100,000 shares at $0.72/share, vesting monthly over 36 months.
- McKhann previously CEO of Silk Road Medical (acquired by Boston Scientific) and Apollo Endosurgery (also acquired by Boston Scientific).
- McKhann is independent under Nasdaq listing standards and SEC rules.
- Appointment effective April 15, 2026; term expires at 2027 annual meeting.

## SEC filing metadata
- accession: 0001213900-26-046197
- form_type: 8-K
- ticker: COCH
- cik: 0001840877
- company_name: Envoy Medical, Inc.
- filed_at: 2026-04-21T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840877/000121390026046197/0001213900-26-046197-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840877/000121390026046197/ea028718601-8k_envoymedical.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-046197
- JSON: https://secwatch.observer/filing/0001213900-26-046197.json
- Plain text: https://secwatch.observer/filing/0001213900-26-046197.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.